Eb Group Sp. z o.o. — Clinical Trial Site

64 Registered trials

26 Currently recruiting

Organisation

Eb Group Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100043233

Address

Ulica Polna 30b, 00-635, Poland

Departments

.
Centrum Zdrowia MDM
Centrum Zdrowia MDM - EB Group Sp. z o.o
Centrum Zdrowia MDM Ul. Inflancka 4A 00-189 Warszawa, Poland
Centrum Zdrowia MDM Ul. Polna 30B 00-635 Warszawa, Poland
Centrum Zdrowia MDM/ MDM Healthcare Center
Endocrinology
Gastroenterology
Klinika Neurologii
MDM Healthcare Center
N/A
NA
Site Name: Centrum Zdrowia MDM/ ul. Inflancka 4A, 00-189 Warszawa

Clinical trials at this site (64)

Search interface

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn… Ended

2023-508777-91-00 Moderately to Severely Active Crohn's Disease 10 2023-05-16
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-511089-36-00 Crohn’s disease 4 2023-03-17
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJ… Ended

2023-506278-10-00 Eosinophilic esophagitis 5 2022-04-22
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2023-509233-39-00 Moderately to Severely Active Ulcerative Colitis 4 2022-01-20
A clinical study of tulisokibart in people with Crohn’s disease (MK-7240-006) Ended

2023-509742-35-00 Crohn's disease 4 2021-11-17
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Ulcerative Colitis 4 2021-09-23
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23
This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use… Ended

2023-503771-13-00 Classic Congenital Adrenal Hyperplasia 4 2021-01-28
This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of… Ended

2023-503770-21-00 Classic Congenital Adrenal Hyperplasia 4 2021-01-05
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Focal segmental glomerulosclerosis (FSGS) 5 2018-10-15
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Moderately to Severely Active Crohn's Disease 5 2018-09-27
A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam in adult and pediatric patients with spi… Ended

2023-506739-14-00 Spinal Muscular Atrophy (SMA) 4 2017-05-12
A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped… Ended

2023-504711-32-00 Ulcerative Colitis 5 2015-11-24
The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the treatment of ulcerative colitis (UC) Ended

2024-514815-92-00 Ulcerative colitis 5 2015-07-16